Cognetivity Neurosciences’ CognICA™ Platform Successfully Monitors Cognitive Performance in Alzheimer’s Patients Receiving Disease-Modifying Therapy
Demonstrable sensitivity and clinical usability of Cognetivity’s screening and monitoring tool leaves the company well placed to support the dawning era of targeted therapies for neurodegenerative disease
VANCOUVER, BC, January 24, 2023 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that its flagship CognICA™ tool has demonstrated effectiveness in tracking cognitive function during the treatment of Alzheimer’s disease patients with the disease-modifying therapy Aduhelm™ (aducanumab), manufactured by Biogen.
CognICA was used in clinical practice at Mediclinic Parkview Hospital in Dubai, UAE, to screen 108 patients coming into the neurology clinic for cognitive impairment. The tool was then used to monitor the cognition of the patients who received a diagnosis of Alzheimer’s disease and were eligible for treatment with Aduhelm, a US Food and Drug Administration (FDA)-approved drug that directly targets amyloid beta pathology.
The results showed that patients who received Aduhelm did not show cognitive decline, with two patients showing a significant improvement in cognitive performance. They demonstrate the use of CognICA as a sensitive screening and monitoring tool to support detection of cognitive impairment and measure changes in cognitive performance in response to disease-modifying therapies for Alzheimer’s.
As such, the tool is perfectly suited to support the dawning era of targeted therapies for neurodegenerative disease – as evidenced by the FDA’s approval, in the first week of 2023, of a second drug directly targeting amyloid beta pathology, Leqembi™ (lecanemab). Early detection and diagnosis will be critical to the rapid, large-scale rollout of this family of therapeutics since they have been approved for early-stage disease, in the form of mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s.
Outstanding sensitivity to early-stage disease – the ability to identify changes in the brain – is CognICA’s greatest strength, as demonstrated in thousands of patients and numerous peer-reviewed publications.
Professor Derk Krieger, Director of the Cognitive Health Clinic at Mediclinic Parkview, who has overseen the research, commented on the announcement: “These are extremely exciting results, given the wider global clinical and regulatory context. Powerful, life-changing drugs are coming to market, targeted towards early-stage cognitive decline. But so far, there has been a lack of tools offering high sensitivity and ease of large-scale rollout, sufficient to support mass testing for early-stage impairment. We have shown that CognICA can function as the missing link in the chain, enabling these therapies to be connected to the millions of people who can benefit from them as we need to be smart in choosing our patients for such treatment programs.”
Dr. Sina Habibi, CEO of Cognetivity, also said: “We are delighted to have partnered with Prof Krieger and Mediclinic Parkview Hospital on this important piece of research. We are hugely excited, not just by the results themselves, of course, but by their implications of what CognICA can achieve on a global scale for millions of patients.”
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.
ON BEHALF OF THE BOARD
Chief Executive Officer and Director
Certain statements included in this news release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “assume” “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.